SI-6603

Phase 2Small molecule

SSeikagaku Corporation

SI-6603 is one of 6 small molecule programs targeting Lumbar Disc Herniation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lumbar Disc HerniationActive, not recruiting

Lumbar Disc HerniationPhase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Lumbar Disc Herniation

#DrugCompanyPhaseTrials

Condoliase

SSeikagaku Corporation

Phase 3

2 2

Kenalog

BBassett Healthcare

Preclinical

1 3

SI-6603

SSeikagaku Corporation

Phase 2

3 4

Platelet Rich Plasma

ZZagazig University

Preclinical

1 5

Conventional Medicine

JJaseng Medical Foundation

Preclinical

1 6

Pharmacological Therapy

FFoundation University Islamabad

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lumbar Disc Herniation3 trials

Clinical Trial to Assess Safety of SI-6603 in Patients With Lumbar Disc Herniation

Completed·SSeikagaku Corporation·Phase 2·NCT01282606·18 enrolled

SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

Completed·SSeikagaku Corporation·Phase 3·NCT03607838·352 enrolled

SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation

Completed·SSeikagaku Corporation·Phase 2/3·NCT00634946·195 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SI-6603. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SI-6603 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SI-6603. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seikagaku Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSeikagaku Corporation

SI-6603

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lumbar Disc Herniation3 trials

References

Drug Info

Quick Facts

Related News